Skip to main content

Real patients, real answers

Only another person living with Ph+ CML in chronic phase can know what it’s like to walk in your shoes. That’s the idea behind SCEMBLIX Peers—actual patients who share their personal experience to answer frequently asked questions (FAQs) in a series of short videos.

Choose your SCEMBLIX Peer

Choose the SCEMBLIX Peer whose experience seems most similar to yours. Please note, SCEMBLIX Peers cannot provide clinical advice or counseling. For medical questions, speak with your doctor.

Lynne's Experience

Lynne’s struggles with side effects

Lynne was diagnosed with Ph+ CML in chronic phase in 2005. Unmanageable side effects led Lynne’s doctor to switch her to different tyrosine kinase inhibitors (TKIs) over the years. Based on her struggles with side effects, Lynne joined the clinical trials for SCEMBLIX in 2015 and has been on treatment ever since.

Al's experience

Al’s experience with multiple TKIs

Having been diagnosed in 1997, Al has a longterm perspective on Ph+ CML in chronic phase and has been prescribed several TKIs. Al joined the clinical trials for SCEMBLIX in 2016 after experiencing a lack of response on other medications and continues to take SCEMBLIX.

Individual results may vary.

SCEMBLIX Peers are actual patients who have been compensated by Novartis Pharmaceuticals Corporation.

Important Safety Information

Before taking SCEMBLIX, tell your doctor about all your medical conditions, including if you:

  • have a history of inflammation of your pancreas (pancreatitis)
  • have a history of heart problems or blood clots in your arteries and veins (types of blood vessels)
  • are pregnant or plan to become pregnant. SCEMBLIX can harm your unborn baby ...

Approved Uses

SCEMBLIX is a prescription medicine used to treat adults with:

  • Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
  • Ph+ CML in CP with the T315I mutation ...